-Advertisement-
-Advertisement-
Journal Scan
Musculoskeletal/Rheumatology

Metronomic Cyclophosphamide Shows Long-Lasting Benefit in Chordoma Patient

Posted on February 27, 2020
Metronomic Cyclophosphamide Shows Long-Lasting Benefit in Chordoma Patient

Chordomas are rare cancerous tumors that affect the spine and can occur anywhere from the base of the skull to the tailbone. Because of how rare these tumors are, systemic treatments have not been well studied. Systemic treatments often include platinum-based chemotherapy in combination with small-molecule tyrosine kinase inhibitors, such as imatinib, lenvatinib, or sorafenib. Once these treatments fail, however, it is unclear how to proceed. A case report described long-lasting clinical and radiological benefit with metronomic cyclophosphamide in a patient who experience uncontrolled pain after experiencing disease progression on cisplatin and imatinib.

Read more here.

Reference

Spalato Ceruso M, Napolitano A, Silletta M, Vincenzi B. Unexpected benefit from an ‘old’ metronomic chemotherapy regimen in advanced chordoma. BMJ Case Rep. 2019;12(6). pii: e228728. doi: 10.1136/bcr-2018-228728.

-Advertisement-
Related Articles
Orthopedic Surgeons Prescribe Less Opioids in States with Access to Medical Cannabis
Mar 21, 2020
Difficulties in Recognizing, Diagnosing Chronic Recurrent Multifocal Osteomyelitis
Mar 20, 2020
Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia Presented at ASHG 2019 Annual Meeting
Mar 15, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-